Impact sur les fonctions cognitives des anticholinergiques prescrits chez les patients âgés de plus de 65 ans pour hyperactivité vésicale

Malfoy, K.; Blanchon, Marie-Ange; Lyonnet, A.; Gonthier, R.

doi:10.1016/j.npg.2008.09.003

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a rule, these compounds should be used only when parkinsonism has actually developed, and when other measures, such as the reduction of antipsychotic dosage or the substitution of the administered drug by another one less prone to induce parkinsonism, were proven ineffective [17] [18]. Indeed, anticholinergics have side effects on cognitive functions, the digestive system and salivary glands [19].…”

Section: Discussionmentioning

confidence: 99%

Use of Antipsychotics: A Study from the French National Insurance Healthcare System Database

Désaméricq¹,

Schürhoff²,

Macquin‐Mavier³

et al. 2015

View full text Add to dashboard Cite

A marked increase in antipsychotic prescriptions has been observed in most countries since the introduction of second-generation antipsychotics. Misuse could partly explain this rise. We described the use of antipsychotic medication in France. This retrospective analysis was conducted on the sample "Echantillon généraliste de beneficiaries" from the French National Insurance Healthcare System. All reimbursements for antipsychotic medications in 2010 were identified. Antipsychotics use was described in terms of patient's profiles and condition of use. In 2010, we identified 11,729 single patients with at least one reimbursement for antipsychotic medication (2.23% of French health insurance beneficiaries). The mean age in the population was 54 (sd 20) years. Forty-one percent had declared psychiatric disorder and 15% had a psychiatric follow-up for unknown diseases. Schizophrenia, others psychosis and personality disorders were the three main diagnoses of psychiatric disease. Patients without declared psychiatric disorders and without psychiatric follow-up accounted for 23% (aged between 15 and 65) and 20% (aged 65 years and over) of the population using antipsychotics. Forty-five percent of patients aged between 15 and 65 had more than 3 months of treatment refunded. Patients aged 65 years and over were 69% without dementia and 47% had more than three months of treatment of antipsychotics refunded during the year. These results suggested that antipsychotic treatments were used in France at long term in particular for patients without declared psychiatric disorder or psychiatric follow-up. G. Désaméricq et al.

show abstract

Section: Discussionmentioning

confidence: 99%